BioClinica Inks Seven New Trident IWR Deals in First Quarter 2011
BioClinica
announced that Trident IWR (interactive web response) has been
selected
by seven new clients in the first quarter of 2011 to help build and deploy complex trials efficiently without the need for programming.
Trident IWR provides clinical operations personnel a way to directly set up, monitor, and maintain randomization and supplies for their clinical trials, in a less costly manner and in a fraction of the time than previous alternatives. Trident IWR does not require programming for each new clinical trial and it configures both web and voice at the same time..
In December of 2010, GlaxoSmithKline signed an
agreement
with BioClinica to standardize on the Trident IWR system, selecting the technology as a way to manage their global trials across Phase I-IV clinical trials.
“Since we launched Trident IWR in October 2010, BioClinica has received incredible industry-wide response,” said Mark Weinstein, CEO of BioClinica. “With seven companies making the decision to standardize their complex trials with Trident IWR in just the first quarter of 2011 alone, we are happy to confirm that our best-in-class solution is successfully providing the efficiencies, cost savings and overall support needed by today’s top pharmaceutical companies.”
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
